Meeting
2020 Gastrointestinal Cancers Symposium
Modified FOLFIRINOX versus sequential chemotherapy（FOLFIRI/FOLFOX）as second-line treatment for advanced pancreatic adenocarcinoma: A real-world analysis.
Authors
Shun Tezuka
Kanagawa Cancer Center, Yokohama, Japan
Shun Tezuka , Makoto Ueno , Satoshi Kobayashi , Manabu Morimoto , Shuhei Nagashima , Yusuke Sano , Hiroyuki Asama , Kuniyuki Kawano , Satoshi Tanaka , Taito Fukushima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 711)
Abstract #
711
Poster Bd #
K22
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).
First Author: Fuxiang Zhou
Poster
2022 ASCO Annual Meeting
The PRODIGE 59-DURIGAST trial: A randomized phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-esophageal junction adenocarcinoma.
First Author: David Tougeron
Poster
2021 ASCO Annual Meeting
Apatinib plus vinorelbine versus vinorelbine for advanced triple-negative breast cancer with failed first or second-line treatment: The NAN trial.
First Author: Doudou Li
Poster
2020 ASCO Virtual Scientific Program
FOLFIRINOX de-escalation in advanced pancreatic cancer (aPC): A multicenter real-life study.
First Author: Hortense Chevalier